# A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

> **NCT04188548** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** LY3484356
- **DRUG:** Abemaciclib
- **DRUG:** Everolimus
- **DRUG:** Alpelisib
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase Inhibitor (AI)
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT04188548
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-10
- **Primary completion:** 2020-06-29
- **Final completion:** 2027-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188548, "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04188548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*